Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Enters LC-Triple Quad Market with Launch of New EVOQ Mass Specs


This story originally ran on Sept. 4.

Bruker this week launched its new triple quadrupole mass spectrometers – the EVOQ Qube and EVOQ Elite.

The instruments, which Bruker launched in conjunction with this week's 2012 Japan Analytical Scientific Instruments Show, are the company's first LC-triple quad releases and expand its offerings in the areas of targeted and clinical proteomics.

Bruker obtained triple-quad technology in 2010 when it purchased three Varian product lines – including a gas chromatography triple-quadrupole mass spec – from Agilent as part of that firm's Varian buy (PM 05/21/2010), and last year, it launched its Scion GC-triple quad platform, but until this week it had not released an LC-triple quad system for proteomics work.

Triple quadrupoles have proven key in mass spec's push toward the clinic, with triple quad-based multiple-reaction monitoring assays emerging as perhaps the most clinically promising mass spec workflow for targeted proteomics research and protein biomarker-based diagnostics.

Bruker has largely focused its clinical proteomics efforts around its MALDI-MS platforms (PM 1/20/2012), but with the release of the EVOQ machines, the company will now offers MRM-MS capabilities as well, joining competitors including AB Sciex, Agilent, Shimadzu, Thermo Fisher Scientific, and Waters.

The instruments feature vacuum-insulated probe heated ESI and active exhaust API ion sources, 14,000 amu/sec scan speeds, 25 msec positive/negative ion switching, and Bruker's lens-free mass filter design, which, the company said, allows for enhanced MRM performance.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.